Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China

You may also be interested in...



A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)

It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.

Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build

Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.

Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build

Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.

Related Content

Latest News
UsernamePublicRestriction

Register

SC077569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel